Asthma is an ailment often caused due to genetic and environmental factors. To put this illness in a layman’s lingo; it is the breathing trouble experienced by a sufferer due to wheezing, coughing, chest conjunction and shortness of breath. However, this health hazard is commonly confused with COPD which is short form for Chronic Obstructive Pulmonary disease which is entirely different from asthma. COPD is a general term that describes a set of progressive respiratory diseases like chronic bronchitis and emphysema. These kinds of diseases occur due to decreased airflow and increased inflammation levels over a lengthy timeframe. Billions of sufferers currently are unknowingly suffering from COPD diseases and most of them are treated for asthma which turns dangerous in some cases so much so there are chances of deaths due to the misleading treatment.
On a global basis, both Asthma and COPD curing drugs have an active market as there is an estimate of around 300 million sufferers worldwide. The world markets asthma drugs are projected to have a CAGR of 5.8% for the span of upcoming years. The asthma drug market was valued at $15.3 billion by the end of 2012 which is forecasted to cross a whopping mark of $20 billion by the finish of 2017. Drugs against the ill effects of asthma are present in the global Pharma industry since ages now, the manufacturing companies these drugs are researching further in order to formulate and produce more advanced drugs that are of a fast acting nature, those which would provide instant relief.
Drug manufacturing giants GlaxoSmithKline’s and AstraZeneca’s added couples of their products Advair and Symbicort in the year 2011 which went viral replacing the then generic drugs in the segment. Out of these, Advair ranked as the largest selling drug at a value of $7,802 million whereas Singulair took the second spot in terms of sales at $5,479 million for the year ended 2011.
There are no specific areas in the world which holds maximum sufferers of these aliments as all nations are facing the crises of protecting their population from these extremely uncomfortable illnesses. The average mortality rate per annum due to asthma runs up to more than 4000 lives, as mentioned above the environment conditions play a vital role as extremely dry, wet or windy climate causes asthma attacks. The ailment is a major problem for the world economies as around 12.8 million school days are missed per year and for adults it counts up to 10.1 million lost work days.
The regular drugs for COPD are ought to have a CAGR of 1.2% and its market is estimated to cross the $5.5 billion mark by the end of 2017. Overall pollution increase around the globe, the addition in number of smokers and other heredity factors are reasons for the increasing drug market for COPD and Asthma. The later especially has a boarder market as it is found in massive number of patients of all age groups, even in the infants and newborns.